Wave Life Sciences/$WVE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Wave Life Sciences
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Ticker
$WVE
Sector
Primary listing
Employees
288
Headquarters
Singapore, Singapore
Website
WVE Metrics
BasicAdvanced
$1.2B
-
-$0.84
-1.37
-
Price and volume
Market cap
$1.2B
Beta
-1.37
52-week high
$15.84
52-week low
$5.28
Average daily volume
2M
Financial strength
Current ratio
2.558
Quick ratio
2.404
Long term debt to equity
9.226
Total debt to equity
14.755
Profitability
EBITDA (TTM)
-139.916
Gross margin (TTM)
-80.88%
Net profit margin (TTM)
-138.24%
Operating margin (TTM)
-152.76%
Revenue per employee (TTM)
$330,000
Management effectiveness
Return on assets (TTM)
-38.90%
Return on equity (TTM)
-171.41%
Valuation
Price to revenue (TTM)
12.903
Price to book
8.73
Price to tangible book (TTM)
8.73
Price to free cash flow (TTM)
-6.057
Free cash flow yield (TTM)
-16.51%
Free cash flow per share (TTM)
-1.289
Growth
Revenue change (TTM)
-14.98%
Earnings per share change (TTM)
35.40%
3-year revenue growth (CAGR)
32.58%
10-year revenue growth (CAGR)
90.15%
3-year earnings per share growth (CAGR)
-25.68%
10-year earnings per share growth (CAGR)
-6.17%
What the Analysts think about WVE
Analyst ratings (Buy, Hold, Sell) for Wave Life Sciences stock.
Bulls say / Bears say
Wave’s Phase 2 FORWARD-53 trial of WVE-N531 in Duchenne muscular dystrophy showed a statistically significant 28.6 % reduction in muscle fibrosis and a 3.8-second Time-to-Rise improvement versus natural history at 48 weeks, underscoring its durability and supporting an FDA-backed NDA pathway in 2026 (GlobeNewswire)
Preclinical INHBE-targeting siRNA candidate WVE-007 produced semaglutide-comparable fat loss and durable silencing in non-human primate studies, highlighting Wave’s PRISM platform versatility in the large obesity market (Nasdaq)
Wave held $208.5 million in cash and equivalents as of June 30, 2025, extending its cash runway into 2027 and reducing near-term dilution risk ahead of key clinical catalysts (Wave Life Sciences Q2 2025 Results)
Revenue recognized in Q2 2025 dropped 56% year-over-year to $8.7 million, reflecting lower GSK milestone recognition and limited diversification of revenue streams (Wave Life Sciences Q2 2025 Results)
Net loss widened to $50.5 million in Q2 2025 from $32.9 million a year ago as R&D and G&A expenses accelerated, intensifying cash burn ahead of meaningful revenue inflection (Wave Life Sciences Q2 2025 Results)
Prior accelerated approvals for DMD therapies such as Vyondys 53 were contingent on confirmatory trials, and any additional FDA requirements could delay WVE-N531’s planned 2026 NDA submission (FDA)
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2025.
WVE Financial Performance
Revenues and expenses
WVE Earnings Performance
Company profitability
WVE News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Wave Life Sciences stock?
Wave Life Sciences (WVE) has a market cap of $1.2B as of October 20, 2025.
What is the P/E ratio for Wave Life Sciences stock?
The price to earnings (P/E) ratio for Wave Life Sciences (WVE) stock is 0 as of October 20, 2025.
Does Wave Life Sciences stock pay dividends?
No, Wave Life Sciences (WVE) stock does not pay dividends to its shareholders as of October 20, 2025.
When is the next Wave Life Sciences dividend payment date?
Wave Life Sciences (WVE) stock does not pay dividends to its shareholders.
What is the beta indicator for Wave Life Sciences?
Wave Life Sciences (WVE) has a beta rating of -1.37. This means that it has an inverse relation to market volatility.